Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 4/20 | 1.00 |
| ▸ | DRD3 | P35462 | 4/20 | 1.00 |
| ▸ | DRD1 | P21728 | 3/20 | 1.00 |
| ▸ | DRD4 | P21917 | 2/20 | 1.00 |
| ▸ | DRD5 | P21918 | 2/20 | 1.00 |
| ▸ | MAPT | P10636 | 9/20 | 0.80 |
| ▸ | MAPK1 | P28482 | 8/20 | 0.80 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.80 |
| ▸ | HPGD | P15428 | 8/20 | 0.80 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.80 |
| ▸ | LMNA | P02545 | 7/20 | 0.80 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.80 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.80 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.80 |
| ▸ | TP53 | P04637 | 5/20 | 0.80 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.80 |
| ▸ | GMNN | O75496 | 4/20 | 0.80 |
| ▸ | PMP22 | Q01453 | 4/20 | 0.80 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.80 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.80 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| R-N-Propylnorapomorphine SCHEMBL13487203 | 0.89 | DRD2 (1.00) | DRD2DRD3DRD1DRD4DRD5 | |
| R-N-Propylnorapomorphine SCHEMBL29447877 | 0.89 | DRD2 (1.00) | DRD2DRD3DRD1DRD4DRD5 | |
| R-N-Propylnorapomorphine SCHEMBL249729 | 0.89 | DRD2 (1.00) | DRD2DRD3DRD1DRD4DRD5 | |
| R-N-Propylnorapomorphine SCHEMBL7997518 | 0.89 | DRD2 (1.00) | DRD2DRD3DRD1DRD4DRD5 | |
| R-N-Propylnorapomorphine SCHEMBL13398114 | 0.89 | DRD2 (1.00) | DRD2DRD3DRD1DRD4DRD5 | |
| SCHEMBL14161595 | 0.86 | MAPT (0.83) | DRD2DRD3DRD1DRD4DRD5 | |
| SCHEMBL15075344 | 0.83 | MAPT (0.74) | DRD2DRD3DRD1DRD4DRD5 | |
| SCHEMBL29753987 | 0.83 | MAPT (1.00) | DRD2DRD3DRD1DRD4DRD5 | |
| SCHEMBL12305056 | 0.83 | MAPT (1.00) | DRD2DRD3DRD1DRD4DRD5 | |
| SCHEMBL12305058 | 0.83 | MAPT (1.00) | DRD2DRD3DRD1DRD4DRD5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230035892-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | FLAGSHIP PIONEERING, INC. | 2023-02-02 | — | — | US | disclosed |
| US-11274158-B2 | Methods and compositions for treating inflammatory or autoimmune diseases or conditions using calcitonin receptor activators | FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) | 2022-03-15 | — | — | US | disclosed |
| US-20220033490-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER USING CHRNA6 INHIBITORS | FLAGSHIP PIONEERING INNOVATIONS V INC (US) | 2022-02-03 | — | — | US | disclosed |
| US-11208475-B1 | Methods and compositions for treating inflammatory or autoimmune diseases or conditions using serotonin receptor activators | FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) | 2021-12-28 | — | — | US | disclosed |
| US-20210283217-A1 | NEUROMODULATING COMPOSITIONS AND RELATED THERAPEUTIC METHODS FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES | FLAGSHIP PIONEERING INNOVATIONS V, INC. | 2021-09-16 | — | — | US | disclosed |
| US-11059886-B1 | Methods and compositions for treating inflammatory or autoimmune diseases or conditions using GRM8 activators | FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) | 2021-07-13 | — | — | US | disclosed |
| US-20210177823-A1 | NEUROMODULATING COMPOSITIONS AND RELATED THERAPEUTIC METHODS FOR THE TREATMENT OF CANCER | FLAGSHIP PIONEERING INNOVATIONS V, INC. | 2021-06-17 | — | — | US | disclosed |
| US-11034751-B1 | Methods and compositions for treating cancer using serotonin receptor inhibitors | FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) | 2021-06-15 | — | — | US | disclosed |
| US-20210154272-A1 | NEUROMODULATING COMPOSITIONS AND RELATED THERAPEUTIC METHODS FOR THE TREATMENT OF CANCER BY MODULATING AN ANTI-CANCER IMMUNE RESPONSE | FLAGSHIP PIONEERING INNOVATIONS V, INC. | 2021-05-27 | — | — | US | disclosed |
| US-11013717-B1 | Methods and compositions for treating cancer using SERCA pump inhibitors | FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) | 2021-05-25 | — | — | US | disclosed |
| US-10683352-B1 | Methods for treating cancer using GRM8 inhibitors | FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) | 2020-06-16 | — | — | US | disclosed |
| US-10457740-B1 | Methods and compositions for treating cancer using P2RX2 inhibitors | FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) | 2019-10-29 | — | — | US | disclosed |
| US-20190240293-A1 | NEUROMODULATING COMPOSITIONS AND RELATED THERAPEUTIC METHODS FOR THE TREATMENT OF CANCER BY MODULATING AN ANTI-CANCER IMMUNE RESPONSE | CYGNAL THERAPEUTICS, INC. | 2019-08-08 | — | — | US | disclosed |
| US-20190233527-A1 | METHODS AND COMPOSITIONS FOR TREATING INFLAMMATORY OR AUTOIMMUNE DISEASES OR CONDITIONS USING CALCITONIN RECEPTOR ACTIVATORS | FLAGSHIP PIONEERING, INC. | 2019-08-01 | — | — | US | disclosed |
| EP-3506926-A1 | NEUROMODULATING COMPOSITIONS AND RELATED THERAPEUTIC METHODS FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES | Flagship Pioneering Innovations V, Inc. (US) | 2019-07-10 | — | — | EP | disclosed |
| EP-3490542-A1 | NEUROMODULATING COMPOSITIONS AND RELATED THERAPEUTIC METHODS FOR THE TREATMENT OF CANCER BY MODULATING AN ANTI-CANCER IMMUNE RESPONSE | Flagship Pioneering Innovations V, Inc. (US) | 2019-06-05 | — | — | EP | disclosed |
| EP-3490581-A2 | NEUROMODULATING COMPOSITIONS AND RELATED THERAPEUTIC METHODS FOR THE TREATMENT OF CANCER | Flagship Pioneering Innovations V, Inc. (US) | 2019-06-05 | — | — | EP | disclosed |
| WO-2018022666-A1 | NEUROMODULATING COMPOSITIONS AND RELATED THERAPEUTIC METHODS FOR THE TREATMENT OF CANCER BY MODULATING AN ANTI-CANCER IMMUNE RESPONSE | FLAGSHIP PIONEERING, INC. (US) | 2018-02-01 | — | — | WO | disclosed |
| WO-2018022664-A1 | NEUROMODULATING COMPOSITIONS AND RELATED THERAPEUTIC METHODS FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES | FLAGSHIP PIONEERING, INC. (US) | 2018-02-01 | — | — | WO | disclosed |
| WO-2018022668-A2 | NEUROMODULATING COMPOSITIONS AND RELATED THERAPEUTIC METHODS FOR THE TREATMENT OF CANCER | FLAGSHIP PIONEERING, INC. (US) | 2018-02-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220033490-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER USING CHRNA6 INHIBITORS | CHRNA6, CHRNA1, CHRNB1 | DRD2 1322/4885DRD3 1699/4885DRD1 3052/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.